US Stock MarketDetailed Quotes

AMPH Amphastar Pharmaceuticals

Watchlist

46.090
-7.310-13.69%

Close Nov 7 16:00 ET

47.190
+1.100+2.39%

Post 16:25 ET

2.23BMarket Cap15.31P/E (TTM)

Amphastar Pharmaceuticals Stock Forum

Analysts Notebook

Sep 5 06:06

Columns 'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio

The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...

Trump returns to the White House! Which industries will benefit in the next four years?

Meltyy

May 23 09:18

$Amphastar Pharmaceuticals (AMPH.US)$ 📣 Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24

Moomoo AI

Jan 19 13:36

The market's growth expectations seem moderated as EPS growth outpaces average annual share price increase. The recent rise in total shareholder return could suggest business improvement over time.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three Years

Moomoo AI

Dec 20, 2023 05:52

The impressive EPS growth and large insider ownership make Amphastar Pharmaceuticals a potentially attractive investment. The business appears to have reached a growth inflection point.

If EPS Growth Is Important To You, Amphastar Pharmaceuticals (NASDAQ:AMPH) Presents An Opportunity

Explore moomoo's "Insider Activity" for institutional sentiment

Moomoo AI

Nov 18, 2023 06:41

Insider ownership is moderately high, showing company's interest for all shareholders, but the lack of insider buying and significant selling over the last year, casts some doubt on the company's outlook.

This Insider Has Just Sold Shares In Amphastar Pharmaceuticals

Moomoo AI

Oct 19, 2023 06:16

Amphastar Pharmaceuticals experienced a dip, but long-term its performance is strong due to profitability transition and faster EPS growth versus share price. However, market growth expectations are moderated. Share price momentum indicates a potential investment opportunity.